{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:12:23Z","timestamp":1792131143732,"version":"4.4.0"},"reference-count":19,"publisher":"American Society of Tropical Medicine and Hygiene","issue":"1","license":[{"start":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,3]]},"abstract":"<jats:title>ABSTRACT.<\/jats:title>\n<jats:p>The profiles of vaccine-induced dengue antibodies may differ from those produced following natural infection and could potentially interfere with the interpretation of diagnostic tests. We assessed anti-dengue IgG and IgM antibodies, and nonstructural protein 1 antigen profiles in the serum of adults who received a single dose of the tetravalent dengue vaccine TAK-003 as either an initially developed high-dose formulation or the standard approved formulation in a phase 2 study in Singapore (#NCT02425098). Immunoglobulin G and IgM profiles during the first 30\u2009days postvaccination varied by baseline serostatus (microneutralization assay). Nonstructural protein 1 antigen was not detected in the serum of any participants. Vaccine-induced IgG and IgM antibodies can affect serological confirmation of subsequent dengue infection in vaccinees. These results highlight the limitations of using serological tests for dengue diagnosis, particularly in a postvaccination setting, and emphasize the need for more sensitive antigen- and molecular-based testing for accurate dengue diagnosis.<\/jats:p>","DOI":"10.4269\/ajtmh.23-0549","type":"journal-article","created":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T18:09:31Z","timestamp":1716919771000},"page":"102-106","source":"Crossref","is-referenced-by-count":5,"title":["IgG, IgM, and Nonstructural Protein 1 Response Profiles after Receipt of Tetravalent Dengue Vaccine TAK-003 in a Phase 2 Randomized Controlled Trial"],"prefix":"10.4269","volume":"111","author":[{"given":"Jenny G.","family":"Low","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Singapore General Hospital, Singapore;"},{"name":"Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen M.","family":"Oh","sequence":"additional","affiliation":[{"name":"Changi General Hospital, Singapore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee-Sin","family":"Leo","sequence":"additional","affiliation":[{"name":"National Centre for Infectious Diseases, Singapore;"},{"name":"Saw Swee Hock School of Public Health, National University of Singapore, Singapore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirin","family":"Kalimuddin","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Singapore General Hospital, Singapore;"},{"name":"Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limin","family":"Wijaya","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Singapore General Hospital, Singapore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junxiong","family":"Pang","sequence":"additional","affiliation":[{"name":"National Centre for Infectious Diseases, Singapore;"},{"name":"Saw Swee Hock School of Public Health, National University of Singapore, Singapore;"},{"name":"SingHealth Duke-NUS Global Health Institute, Duke-NUS Medical School, Singapore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tau Hong","family":"Lee","sequence":"additional","affiliation":[{"name":"Tan Tock Seng Hospital, Singapore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelley J.","family":"Moss","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc., Cambridge, Massachusetts;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manja","family":"Brose","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc., Cambridge, Massachusetts;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vianney","family":"Tricou","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International AG, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2795","reference":[{"key":"b1","year":"2023"},{"key":"b2","year":"2019"},{"key":"b3","year":"2023"},{"key":"b4","series-title":"J Clin Virol","first-page":"179","article-title":"Laboratory diagnosis of primary and secondary dengue infection","volume":"31","author":"Schilling","year":"2004"},{"key":"b5","series-title":"Trans R Soc Trop Med Hyg","first-page":"653","article-title":"A review of dengue diagnostics and implications for surveillance and control","volume":"113","author":"Raafat","year":"2019"},{"key":"b6","series-title":"Clin Infect Dis","first-page":"1164","article-title":"Impact of dengue vaccination on serological diagnosis: Insights from phase III dengue vaccine efficacy trials","volume":"66","author":"Plennevaux","year":"2018"},{"key":"b7","series-title":"Vaccine","first-page":"2707","article-title":"Detection of dengue cases by serological testing in a dengue vaccine efficacy trial: Utility for efficacy evaluation and impact of future vaccine introduction","volume":"34","author":"Plennevaux","year":"2016"},{"key":"b8","series-title":"Nat Rev Microbiol","first-page":"S30","article-title":"Evaluation of diagnostic tests: Dengue","volume":"8","author":"Peeling","year":"2010"},{"key":"b9","series-title":"BMC Infect Dis","first-page":"142","article-title":"Comparison of two dengue NS1 rapid tests for sensitivity, specificity and relationship to viraemia and antibody responses","volume":"10","author":"Tricou","year":"2010"},{"key":"b10","series-title":"Science","first-page":"745","article-title":"Cross-reacting antibodies enhance dengue virus infection in humans","volume":"328","author":"Dejnirattisai","year":"2010"},{"key":"b11","series-title":"PLoS Negl Trop Dis","first-page":"e2243","article-title":"Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax)","volume":"7","author":"Huang","year":"2013"},{"key":"b12","series-title":"J Virol","first-page":"3011","article-title":"Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5\u2032 noncoding region and nonstructural proteins 1 and 3","volume":"74","author":"Butrapet","year":"2000"},{"key":"b13","series-title":"Lancet","first-page":"1434","article-title":"Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2\u201317 years: A randomised, placebo-controlled, phase 2 trial","volume":"395","author":"Tricou","year":"2020"},{"key":"b14","series-title":"Lancet Glob Health","first-page":"e257","article-title":"Long-term efficacy and safety of tetravalent dengue vaccine (TAK 003): 4\u00b75-year results from a phase 3, randomised, double-blind, placebo-controlled trial","volume":"12","author":"Tricou","year":"2024"},{"key":"b15","series-title":"Vaccine","first-page":"1513","article-title":"Safety and immunogenicity of a single dose of a tetravalent dengue vaccine with two different serotype-2 potencies in adults in Singapore: A phase 2, double-blind, randomised, controlled trial","volume":"38","author":"Tricou","year":"2020"},{"key":"b16","series-title":"Ann Lab Med","first-page":"566","article-title":"Comparison of six commercial diagnostic tests for the detection of dengue virus non-structural-1 antigen and IgM\/IgG antibodies","volume":"39","author":"Lee","year":"2019"},{"key":"b17","series-title":"J Infect Dis","first-page":"1282","article-title":"Antibodies produced in response to a live-attenuated dengue vaccine are functional in activating the complement system","volume":"227","author":"Nascimento","year":"2023"},{"key":"b18","series-title":"Epidemiol Infect","first-page":"820","article-title":"Specific IgM and IgG responses in primary and secondary dengue virus infections determined by enzyme-linked immunosorbent assay","volume":"134","author":"Sa-Ngasang","year":"2006"},{"key":"b19","series-title":"J Clin Virol","first-page":"185","article-title":"Analysis of specific IgM responses in secondary dengue virus infections: Levels and positive rates in comparison with primary infections","volume":"31","author":"Chanama","year":"2004"}],"container-title":["The American Journal of Tropical Medicine and Hygiene"],"original-title":[],"link":[{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/111\/1\/article-p102.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/111\/1\/article-p102.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/111\/1\/article-p102.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T13:33:09Z","timestamp":1720013589000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/111\/1\/article-p102.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,3]]},"references-count":19,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.4269\/ajtmh.23-0549","relation":{},"ISSN":["0002-9637","1476-1645"],"issn-type":[{"value":"0002-9637","type":"print"},{"value":"1476-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,3]]}}}